General

Cell Line

hPSCreg name SCTi003-A-1
Cite as:
SCTi003-A-1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 26th August 2025
Notes Genome-edited Human iPSC Line, SCTi003-A-1, APOE e4/e4 (SCTi003-A-1) was generated by CRISPR/Cas9 technology, which converted the endogenous apolipoprotein E (APOE) allele APOE ε3 to APOE ε4, resulting in a homozygous APOE ε4/ε4 genotype. APOE ε4 has one of the highest risk scores for late-onset Alzheimer’s disease (AD) and is associated with increased amyloid-β deposition, neuroinflammation, and impaired lipid metabolism (Ayyubova; Garcia et al.).

This product’s parental human induced pluripotent stem cell (hiPSC) line, Healthy Control Human iPSC Line, Female, SCTi003-A, is a well-characterized control line derived from peripheral blood mononuclear cells (PBMCs) from a 48-year-old healthy donor originally heterozygous for APOE ε3/ε4. Targeted gene modifications were confirmed by Sanger sequencing. Post-editing, extensive quality control procedures were undertaken in the manufacturing process for SCTi003-A-1 to ensure optimal product performance and reproducibility. SCTi003-A-1 is karyotypically stable, expresses markers of the undifferentiated state, and remains capable of directed differentiation into all three germ layers, including neural lineage cells relevant for Alzheimer’s disease research. This genome-edited hiPSC line, along with its parental hiPSC line, provides a genetically defined tool for modeling APOE-related mechanisms in Alzheimer’s disease and for preclinical evaluation of targeted therapeutics.

SCTi003-A-1 is manufactured with mTeSR™ Plus (Catalog #100-0276) and is compatible with STEMdiff™ cell culture media products, allowing for standardized high-quality maintenance and differentiation to various cell types, such as neurons, astrocytes, and microglia.

Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator STEMCELL Technologies Inc. (SCT)
Owner STEMCELL Technologies Inc. (SCT)
Distributors
Derivation country United States

External Databases

BioSamples SAMEA119557645

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Self-declared race/ethnicity = White
Ancestry = 100% European

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA11371632

Ethics

Also have a look at the ethics information for the parental line SCTi003-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line SCTi003-A.

Reprogramming method

Vector type Non-integrating
Vector Proprietary non-integrating reprogramming technology
Is reprogramming vector detectable?
No
Methods used
PCR
Notes on reprogramming vector detection Clearance confirmed at passage 21

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
ReLeSR™
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
Figure 2. SCTi003-A-1 Human iPSCs Demonstrate High-Quality Morphology in Routine Culture.

Cryopreserved cells from the SCTi003-A-1 line were thawed and maintained in mTeSR™ Plus on Corning® Matrigel® Matrix. (A) The resulting iPSC colonies have densely packed cells and show multi-layering when ready to be passaged. (B,C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios. iPSC = induced pluripotent stem cell.
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
CXCR4
Yes
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
TBXT
Yes
NCAM1
Yes
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
NES
Yes
Protocol or reference

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 37

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 37
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Exome sequencing
Whole exome sequencing data file (Catalog #500-0705) is available upon request for a fee for SCTi003-A-1 customers. Please contact iPSCrequests@stemcell.com for more information.
SNP typing array
SNP microarray data is included in each lot-specific COA. Please contact iPSCrequests@stemcell.com for more information.
Genome sequencing
Whole genome sequencing data file (Catalog #500-0706) is available upon request for a fee for SCTi003-A-1 customers. Please contact iPSCrequests@stemcell.com for more information.

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Alzheimer's Disease
  • Alzheimer disease
  • Alzheimer Disease
  • Alzheimer dementia
  • Alzheimer's Dementia
  • Alzheimer's disease
  • Alzheimer's disease, unspecified
show more synonyms
Genetic modifications
APOE apolipoprotein E [Homo sapiens (human)] (target)
Isogenic modification
19q13.32
NM_000041.4:c.388T>C
NP_000032.1:p.Cys112Arg
Homozygous
The SCTi003-A-1 iPSC line was derived from the parental SCTi003-A line, which originated from a healthy female donor with an APOE e3/e4 genotype. Using CRISPR-Cas9 genome editing, a single nucleotide substitution (c.388T>C) was introduced on the e3 allele in exon 4 of the APOE gene (NM_000041.4) at SNP rs429358. This change converted codon 112 from cysteine (Cys) to arginine (Arg), resulting in the p.Cys112Arg (C112R) substitution and producing a homozygous APOE e4/e4 genotype. This engineered line models the APOE e4/e4 genotype, a variant strongly linked to increased Alzheimer’s disease risk, and serves as a well-characterized genetic model for disease research and therapeutic testing.
Mutated